肺癌获得性多药耐药机制的研究进展  

Study progress on formation mechanism of multidrug resistance of lung cancer

作　　者：梁丽峰[1] 戢福云[2] 马李杰[1] 赵诣林[1] 陈向军[1] 金发光[1] 

机构地区：[1]第四军医大学唐都医院呼吸与危重症医学科,西安710038 [2]第三军医大学新桥医院全军呼吸内科研究所,重庆400037

出　　处：《国际呼吸杂志》2014年第14期1111-1115,共5页International Journal of Respiration

基　　金：国家自然科学基金（81071933）

摘　　要：肺癌对人类健康的危害日益严重，从20世纪中叶开始，其发病率和病死率在全球范围内迅速增长，而患者的5年生存率却徘徊在10％左右。化疗是肺癌综合治疗的重要手段之一，然而近年来，多药耐药的不断出现严重限制了肺癌化疗效果的提高。多药耐药机制的研究有望为逆转耐药提供全新的思路。Lung cancer is becoming increasingly serious harm to human health. From the mid-20th century,its morbidity and mortality are growing fast around the world, but 5-year survival rate of the patients is hovering at 10 % approximately. Chemotherapy is one of the important means of comprehensive treatment of lung cancer, however, in recent years, the continual emergence of multi-drug resistance severely limits the improvement of lung cancer chemotherapy. And, the research of the multi-drug resistance mechanism is expected to provide a new train of thought to reverse drug resistance.

关 键 词：肺癌 多药耐药 获得性 

分 类 号：R734.2[医药卫生—肿瘤]